@article{0a4303a900d14440acdce2ff27e4047b,
title = "Patient selection biomarker strategies for PARP inhibitor therapy",
author = "Pili{\'e}, {P. G.} and A. George and Yap, {T. A.}",
note = "Funding Information: MD Anderson Cancer Center Support Grant (P30 CA016672) for TAY. TAY is a V Foundation V Clinical Scholar (VC2020-001). TAY has received research support (to institution) from Artios, AstraZeneca, Bayer, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star, GlaxoSmithKline, Genentech, ImmuneSensor, Ipsen, Jounce, Karyopharm, Kyowa, Merck, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Repare, Sanofi, Scholar Rock, Seattle Genetics, Tesaro, and Vertex Pharmaceuticals; reports consulting for Almac, Aduro, AstraZeneca, Atrin, Axiom, Bayer, Bristol Myers Squibb, Calithera, Clovis, Cybrexa, EMD Serono, F-Star, Guidepoint, Ignyta, I-Mab, Jansen, Merck, Pfizer, Repare, Roche, Rubius, Schrodinger, Seattle Genetics, Varian, and Zai Labs Patrick. AG reports consulting/honoraria (to department or self) for/from Astra Zeneca, Clovis, GSK, Merck, Pfizer, Roche. PGP has declared no conflicts of interest.",
year = "2020",
month = dec,
doi = "10.1016/j.annonc.2020.09.017",
language = "English (US)",
volume = "31",
pages = "1603--1605",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "12",
}